Literature DB >> 9421109

Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies.

C Le Guellec1, M L Gaudet, S Lamanetre, M Breteau.   

Abstract

Interest in determining plasma levels of rifampin for adjustment of dosage regimens has increased, but conflicting results exist concerning rifampin stability. The authors developed a high-performance liquid chromatography assay to monitor rifampin plasma concentrations that was used to study the possible degradation of rifampin in plasma samples. This report describes the stability of rifampin in plasma kept at an ambient temperature for 24 hours or stored at -20 degrees C for 2 weeks. The possible protective effect of adding ascorbic acid was also studied. The results indicate that rifampin degrades rapidly in plasma at an ambient temperature, and a 54% loss was observed within 8 hours. This degradation can be effectively prevented by adding ascorbic acid, thus prolonging stability for up to 12 hours. The same results were observed with samples obtained as part of routine drug monitoring. Degradation was found to be greater at low rifampin concentrations. The authors subsequently demonstrated that decomposition of rifampin occurs after storage for 1 week at -20 degrees C. However, in samples supplemented with ascorbic acid before freezing, no degradation was observed within 14 days at the two concentrations tested. Rifampin was more stable in specimens drawn from treated patients, suggesting possible in vivo stabilization of the molecule. Further studies are needed to determine stability of rifampin for longer storage periods. On the basis of these results, plasma samples obtained from patients receiving rifampin should be immediately supplemented with ascorbic acid and analyzed as soon as possible.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421109     DOI: 10.1097/00007691-199712000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.

Authors:  L Aït Moussa; O El Bouazzi; S Serragui; D Soussi Tanani; A Soulaymani; R Soulaymani
Journal:  Ther Adv Drug Saf       Date:  2016-09-07

2.  Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients.

Authors:  E Ribera; L Pou; A Fernandez-Sola; F Campos; R M Lopez; I Ocaña; I Ruiz; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

Authors:  Alvaro A Ordonez; Hechuan Wang; Gesham Magombedze; Camilo A Ruiz-Bedoya; Shashikant Srivastava; Allen Chen; Elizabeth W Tucker; Michael E Urbanowski; Lisa Pieterse; E Fabian Cardozo; Martin A Lodge; Maunank R Shah; Daniel P Holt; William B Mathews; Robert F Dannals; Jogarao V S Gobburu; Charles A Peloquin; Steven P Rowe; Tawanda Gumbo; Vijay D Ivaturi; Sanjay K Jain
Journal:  Nat Med       Date:  2020-02-17       Impact factor: 53.440

4.  Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS.

Authors:  Lee C Winchester; Anthony T Podany; Joshua S Baldwin; Brian L Robbins; Courtney V Fletcher
Journal:  J Pharm Biomed Anal       Date:  2014-11-18       Impact factor: 3.935

5.  Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  J M Miró; C García-de-la-Mària; Y Armero; D Soy; A Moreno; A del Río; M Almela; M Sarasa; C A Mestres; J M Gatell; M T Jiménez de Anta; F Marco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

6.  Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.

Authors:  P Martin; R Riley; D J Back; A Owen
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

7.  Serum Rifampicin Levels in Patients with Tuberculosis : Effect of P-Glycoprotein and CYP3A4 Blockers on its Absorption.

Authors:  Jai Prakash; Thirumurthy Velpandian; Jitender N Pande; Suresh K Gupta
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

8.  Processing and sustained in vitro release of rifampicin containing composites to enhance the treatment of osteomyelitis.

Authors:  Niina Ahola; Minna Veiranto; Noora Männistö; Matti Karp; Jaana Rich; Alexander Efimov; Jukka Seppälä; Minna Kellomäki
Journal:  Biomatter       Date:  2012 Oct-Dec

9.  Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection.

Authors:  Behnam Dasht Bozorg; Ali Goodarzi; Fanak Fahimi; Payam Tabarsi; Nahid Shahsavari; Farzad Kobarfard; Farzaneh Dastan
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

10.  Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).

Authors:  David Ekqvist; Anna Bornefall; Daniel Augustinsson; Martina Sönnerbrandt; Michaela Jonsson Nordvall; Mats Fredrikson; Björn Carlsson; Mårten Sandstedt; Ulrika S H Simonsson; Jan-Willem C Alffenaar; Jakob Paues; Katarina Niward
Journal:  BMJ Open       Date:  2022-03-10       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.